Light Cured Resin Modified Calcium Silicate Versus Light Cured Calcium Hydroxide in Indirect Pulp Treatment of Primary Molars
Launched by CAIRO UNIVERSITY · Dec 29, 2018
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
To evaluate clinical and radiographic success of resin modified calcium silicate in comparison to light cured calcium hydroxide as indirect pulp capping materials in primary molars.
P: Children aged (4-7 years) with deep carious lesions in lower primary second molars indicated for indirect pulp treatment.
I: Indirect pulp treatment using light cured resin modified Calcium Silicate (TheraCal).
C: Indirect pulp treatment using light cured Calcium Hydroxide. O: clinical and radiographic success.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Medically free children.
- • 2. Age range from 4-7 years.
- • 3. Presence of lower second primary molars with deep carious occlusal lesion.
- • 4. No history of spontaneous pain (reversible pulpitis).
- • 5. Clinically: Absence of swelling, sinus, fistula, pain on percussion and tooth mobility.
- • 6. Radiographically: Absence of radiolucent lesions at furcation or periapical region and absence of internal or external root resorption.
- Exclusion Criteria:
- • 1. Uncooperative children.
- • 2. Any unmet previous criterion.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials